PH-ICKPD1-02/21-(INTACT/MeRCI)

The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for anti-PD1 refractory unresectable stage III-IV melanoma.

ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT06284590?viewType=Card&id=MeRCI&rank=1

Locations: Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut

Contact: Holly Maheu: holly.maheu@hhchealth.org